Rheumatoid Arthritis | Pfizer Información Médica

Materiales de Congresos

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver al áreas de Enfermedades

Presentación Oral

Kristensen LE, Strober B, Poddubnyy D, Leung Y-Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman DD Junio 1, 2022 EULAR 2022 Artritis Psoriásica

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

Ver Presentación

Póster

Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Ytterberg SR, Koch GG, Wu J, Wang C, Kwok K, Menon S, Chen Y, Cesur TY, Rivas JL, Yndestad A, Diehl A, Bhatt DL Junio 1, 2022 EULAR 2022 Artritis Reumatoidea

Association between baseline statin treatment and major adverse cardiovascular events in patients with rheumatoid arthritis: a post hoc analysis of ORAL Surveillance

Ver Presentación

Póster

Wright GC, Mysler E, Chen Y-H, Kinch C, Yndestad A, Kwok K, Cadatal MJ, Germino R, Ogdie A Junio 1, 2022 EULAR 2022 Artritis Reumatoidea

Impact of race on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of Phase 2, 3 and 3b/4 clinical trials

Ver Presentación

Póster

Waddington JC, Zhou R, Coleman O, Wundervald B, Parnell A, Mease PJ, Chandran V, Fallon L, Chapman D, Pollock R, Deng S, FitzGerald O, Pennington SR Junio 1, 2022 EULAR 2022 Artritis Psoriásica

Mass spectrometry-based proteomics for the identification of candidate serum protein biomarkers that may predict treatment response in patients with psoriatic arthritis

Ver Presentación

Póster

Karpouzas G, Szekanecz Z, Baecklund E, Mikuls T, Bhatt DL, Shi H, Wang C, Sawyerr G, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M Junio 1, 2022 EULAR 2022 Artritis Reumatoidea

Relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or TNF inhibitors: a post hoc analysis of ORAL Surveillance

Ver Presentación

Póster

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z Junio 1, 2022 EULAR 2022 Artritis Reumatoidea

Risk factors for major adverse cardiovascular events in patients aged ≥50 years with rheumatoid arthritis and ≥1 additional cardiovascular risk factor: a post hoc analysis of ORAL Surveillance

Ver Presentación

Presentación Oral

Dougados M, Taylor PC, Bingham CO, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M Junio 1, 2022 EULAR 2022 Artritis Reumatoidea, Artritis Psoriásica

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis with complete control of inflammation

Ver Presentación

Póster

Szekanecz Z, Giles JT, Buch MH, Ytterberg SR, Dougados M, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Charles-Schoeman C Junio 2, 2022 EULAR 2022 Artritis Reumatoidea

Incidence of major adverse cardiovascular events stratified by geographic region and baseline cardiovascular risk: a post hoc analysis of ORAL Surveillance

Ver Presentación

Presentación Oral

Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin D, Weitz JI Junio 3, 2022 EULAR 2022 Artritis Reumatoidea

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Ver Presentación

Presentación Oral

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH Junio 3, 2022 EULAR 2022 Artritis Reumatoidea

Impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Ver Presentación